RESEARCH CURRICULUM VITAE

January 2015

NAME AND ADDRESS Richard G. Gower, M. D., FACAAI, FAAAAI, FACP
823 W. 7th Avenue
Spokane, WA 99204
Phone: 509 879 4523 cell
Email: rgower@marycliffallergy.com

PROFESSIONAL STATUS

Current

Marycliff Allergy Specialists, PS, 2006-Present
Allergy, Asthma & Clinical Immunology Clinic
Clinical Research Facility, Principal Investigator
823 West 7th Avenue
Spokane, WA 99204
Phone: (509) 838 3655
Fax: (509) 838 1952
Email: rgower@marycliffallergy.com

Premier Clinical Research
Principal Investigator
324 South Sherman Street, A2
Spokane, WA 99202

Clinical Associate Professor of Medicine,
University of Washington School of Medicine
Seattle, WA

Past

Partner-Rockwood Clinic, 1977-2006
400 East 5th Avenue
Spokane, WA 99202
Phone: (509) 838 2531

UNIVERSITIES ATTENDED

Wabash College, Crawfordsville, Indiana, 1964-1968
Major: Biology
Minor: Chemistry
A. B. Degree Cum Laude

University of Colorado School of Medicine,
Denver, Colorado, 1968-1972
Doctor of Medicine Degree, May 24, 1972

PROFESSIONAL TRAINING

Externship: Radiology. General Rose Memorial Hospital, Denver, Colorado, summer 1970

Rural Preceptorship: General Practice. Craig, Colorado, summer 1971

Internship: Straight Medicine. University of Miami Affiliated Hospitals, Miami, Florida. Hospitals: Jackson Memorial, Veterans Administration, National Children's Cardiac Hospital, July 1972 - June 1973

Residency: Internal Medicine. University of Miami Affiliated Hospitals, Miami, Florida. Hospitals: Jackson Memorial, Veteran's Administration, Mt. Sinai, July 1973 - June 1975

Fellowship: Allergy and Clinical Immunology, Vasculitis. University of Colorado Medical Center Hospitals: Colorado General, Veterans Administration, Denver General, National Jewish Hospital, Fitzsimmons Army Hospital, Children's Asthma Research Institute and Hospital, July 1975 - June 1977

EXTRACURRICULAR ACADEMIC TRAINING

Wabash College:

Laboratory Instructor, invertebrate zoology, fall semester 1966
Laboratory Instructor, morphogenesis of vertebrates, spring semester, 1967
Faculty Instructor, general biology, 1967 - 1968

EXTRACURRICULAR ACADEMIC TRAINING (cont'd)

Medical School:

Research in radiation and health physics, Department of Radiology, University of Colorado Medical School, summer 1968

Research fellowship grant for work in tagging red blood cells with chromium-51 and developing a liquid scintillation counting technique for counting the tagged globin portion of the hemoglobin molecule, Department of Radiology, University of Colorado Medical Center, summer 1969

Morgue diener, Department of Pathology, General Rose Memorial Hospital, Denver, Colorado, summer 1970

Internship-Residency:

Emergency Room Work (extracurricular):
Memorial Hospital, Hollywood, Florida, 1973, 1974, 1975
South Miami Hospital, Miami, Florida, 1974, 1975
Lauderdale Lakes Hospital, Ft. Lauderdale, Florida, 1974, 1975

Fellowship:

Principal coordinator of an ongoing vasculitis study group
Attending physician in Colorado General's Allergy Clinic, 1976-1977
Emergency Room Work (extracurricular), 1975-1977

CERTIFICATION

National Board of Medical Examiners Parts 1, 2, and 3 (Diplomate)
Florida State Boards
Colorado Basic Science Boards
American Board of Internal Medicine - Board Certified 1975 (Diplomate)
American Board of Allergy and Immunology - Board Certified 1977(Diplomate)
American College of Allergy, Asthma, and Immunology (ACAAI) – Fellow, 1986
American College of Physicians – Fellow, 2006
American Academy of Allergy, Asthma, and Immunology–Fellow, 2008
Good Clinical Practice Training: May 2010, May 2011 & May 2012
Good Clinical Practice Training through Transcelerate December, 2013

PHARMACEUTICAL STUDIES

1. Asthma Study (Tilade, Fisons), Principal Investigator, summer 1993.

2. Allergic Rhinitis Study (Rhinocort, Astra), Principal Investigator, summer 1994.

3. Asthma Study (Serevent, Glaxo 5001), Principal Investigator, 1994-1995.

4. Sinusitis Study (Vantin, Upjohn), Principal Investigator, 1995-1997.

5. Asthma Study (MK-0476, Merck), Subinvestigator, 1994-1995.

6. Herpes Zoster Study (Famciclovir, Smith, Kline, Beecham), Principal Investigator, 1995.

7. Asthma Study (Vanceril, Schering/Key), Principal Investigator, spring 1995.

8. Asthma Study (Powdered Salmeterol, Diskus, Glaxo 3011), Principal Investigator, 1995-1996.

9. Asthma Study (Intal, Fisons Corporation), Sub-investigator, 1995-1996.

10. Asthma Study (Pranlukast, Anti-leukotriene, SmithKline Beecham), Principal Investigator, 1995-1996.

11. Asthma Study (Azmacort HFA-134a non-CFC propellant study, Rhone-Poulenc Rorer), Principal Investigator, 1995-1996.

12. Asthma Study (Sepracor 051-024, R-Albuterol in the Reversal of Broncho-constriction and in the Management of Asthma, Phase III), Principal Investigator, 1996-1997.

13. Skin Testing (Evaluation of English Plantain Proposed Reference using the SARAH Method, AF-95-001, Bayer Corporation), Principal Investigator, 1996.

14. Asthma Study, C96-137 (Placebo-Controlled Efficacy and Safety Study with Long-Term Safety Evaluation of Mometasone Furoate Dry Powder in Reducing Oral Steroid Requirements in Patients with Severe Asthma; Schering-Plough, Phase III), Principal Investigator, 1996-1998.

PHARMACEUTICAL STUDIES (cont'd)

15. Bronchitis Study (Acute Exacerbation of Chronic Bronchitis, Bay 12-8039, Phase II, Bayer Corporation), Principal Investigator, 1996-1997.

16. Sinusitis Study (Acute Bacterial Maxillary Sinusitis, Bay 12-8039/Protocol #D96-023, Phase II, Bayer Corporation), Principal Investigator, 1996-1999.

17. Bronchitis Study (Acute Bronchitis, M96-456, Phase III, Abbott Pharmaceuticals), Principal Investigator, 1997.

18. Asthma Study (Pranlukast, Phase III, SkB, SB205312), Principal Investigator, 1996-97.

19. Asthma Study (Schering-Plough C-96-196, Phase III), Principal Investigator, 1997-1998.

20. COPD Study (SLGA-4021: A Comparison of Salmeterol Versus Theophylline versus Salmeterol Plus Theophylline in COPD Patients), Glaxo Wellcome, Inc., 1997-1998.

21. Asthma Study (Spokane Epidemiologic Survey of Asthma, University of Washington School of Medicine), Coinvestigator, 1997-1998.

22. Asthma Study (Schering-Plough C97-223, Phase III), Principal Investigator, 1997-1998.

23. Asthma Study (Schering-Plough C97-224, Phase III), Principal Investigator, 1997-1998.

24. Asthma Study (Zeneca Study No. 91 88IL/0150:0020, Phase III), Principal Investigator, A Multicenter Double-Blind Comparison of Zafirlukast With Placebo in Pediatric Subjects with Mild-to-Moderate Asthma, Principal Investigator, 1997-1998.

25. Chronic Bronchitis Study (Abbott, Phase III, M97-766), Principal Investigator, 1997-1998.

26. Asthma Study (Schering-Plough C-98-005-09, Pediatric, Phase III), Principal Investigator, 1998-1999. Placebo Controlled Efficacy and Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler in the Treatment of Asthma in Children Previously Maintained on Inhaled Corticosteroids

27. Asthma Study (Sepracor, Xopenex Solution, Phase IV), Principal Investigator, 1998-1999.

PHARMACEUTICAL STUDIES (cont'd)

28. Reversible Obstructive Airways Disease Study (Novartis CGP25827A/073, Formoterol, Phase III), Principal Investigator, 1998-1999. Randomized Parallel Group Open Label Multicentered Clinical Study Comparing the Safety, Efficacy, Quality of Life, and Socioeconomic Variables of Twice Daily Formoterol Powder (12 micrograms bid) to Twice Daily Salmeterol (50 micrograms bid) Administered for Six Months to Adult Subjects with ROAD

29. COPD Study (SmithKline Beecham, Ariflo, SB207499/039, Phase IIIA), Principal Investigator, 1998-1999. A 24-Week Double Blind Placebo Controlled Randomized Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ariflo (15 mg bid) in Patients with COPD

30. COPD Study (Glaxo FLTA3025, Phase III) Principal Investigator, 1998-1999. A Randomized Double-Blind Parallel-Group Comparative Trial of Inhaled Fluticasone Proprionate Via the Diskus...in Patients with COPD

31. Allergic Rhinitis/Seasonal Asthma Study (Schering-Plough P97-293, Phase IV), Principal Investigator, 1998-1999.

32. Asthma Study, Named Patient (Astra, Pulmicort Respules, Study #04-3121, Phase IV), Principal Investigator, 1998-1999.

33. Asthma Study, (SKB, CPMS Protocol: SB2445063-006, Phase IIA, IL-5), Principal Investigator, 1998-1999. A Multicenter, Double-Blind, Placebo-, Controlled Randomized Study to Evaluate the Safety and Efficacy of SB240563 in Patients with Moderate Asthma

34. Asthma Study, (Glaxo Wellcome, SAS40021: Phase IV), Principal Investigator, 1999-2000. A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg BID Via the DISKUS Inhaler Versus Oral Montelukast 10mg QD in Adolescents and Adults with Persistent Asthma

35. Influenza Study in Asthma and COPD, (Glaxo Wellcome, NAI30008), Principal Investigator, 1999-2000. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Influenza in Patients 12 Years or Over Diagnosed with Asthma or Chronic Obstructive Pulmonary Disease

36. Seasonal Allergic Rhinitis Study (Schering-Plough Pol376-32). Principal Investigator, summer/fall 2000. Efficacy and Safety of Desloratadine 5 mg Tablet in the Treatment of Subjects 12-17 Years of Age with Seasonal Allergic Rhinitis

PHARMACEUTICAL STUDIES (cont'd)

37. Asthma Study (GlaxoSmithKline, FAP 30007, Phase III). Principal Investigator, 2000-2001. A Randomized, Double-Blind, Parallel Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88 mcg BID, 220 mcg BID, and 440 mcg BID versus Placebo in Propellant GR 1066 42 X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteriod Therapy

38. Asthma Study (GlaxoSmithKline FAP 30008, Phase III). Principal Investigator, 2000-2001. A Randomized Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88 mcg BID, 220 mcg BID and 440 mcg BID versus Placebo in Propellant GR 106642 X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy

39. COPD Study (GlaxoSmithKline SMS40315, Phases III), Principal Investigator, 2000-2001. A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8 Week Comparison of Salmeterol Xinafoate Versus Salmeterol Xinafoate plus Ipratropium Bromide Versus Placebo in Subjects with COPD

40. Sinusitis Study (Abbott, ABT-773, Protocol MOO-225, Phase III). Principal Investigator, 2000-2001. Comparative Study of the Safety and Efficacy of ABT-773 150 mg. QD versus 150 mg. BID for the Treatment of Acute Bacterial Sinusitis

41. Asthma Study, Pediatric (Aventis XRP1526B-341, Phase III). Principal Investigator, 2001. Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 50 mcg/day, 100 mcg/day, and 200 mcg/day (Ex-Valve) Administered Once Daily for 12 Weeks in the Treatment of Children with Persistent Asthma

42. Asthma Study, Pediatric (Aventis XRP1526B-341 LT, Phase III). Principal Investigator, 2001. A Multicenter, Open-Label, One Year Long Term Safety Study of Ciclesonide Metered Dose Inhaler 50 mcg/day to 200 mcg/day (ex-valve) Administered once daily for the Treatment of Children with Persistent Asthma

43. Asthma Study, Adolescents and Adults (Aventis 251526-321, Phase III). Principal Investigator, 2001. Double-Blind, Placebo-controlled, Parallel-group, Multicenter Efficacy, Safety and Dose Response Study of Ciclesonide Metered Dose Inhaler 100 mcg/day, 200 mcg/day, and 400 mcg/day (ex-valve) Administered Once Daily for 12-Weeks in the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults

PHARMACEUTICAL STUDIES (cont'd)

44. Asthma Study (Aventis XRP1526B-326, Phase III). Principal Investigator, December 2001. A Multicenter, Open-label, Long-Term (1 year) Safety Study of Ciclesonide 100 micrograms/day to 400 micrograms/day (Ex-Valve) Metered Dose Inhaler Administered Once Daily For the Treatment of Mild to Moderate Persistent Asthma in Adolescents and Adults.

45. COPD Study (GlaxoSmithKline, SCO30003, TORCH). Principal Investigator, 2001-2004. A Multicentre, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Investigate the Long-Term Effects of Salmeterol/Fluticasone Propionate (Seretide/Viani/Advair) 50/500 mcg bd, Salmeterol 50 mcg bd and Fluticasone Propionate 500 mcg bd, all Delivered Via the Diskus/Accuhaler Inhaler, on the Survival of Subjects with COPD over 3 years of Treatment

46. COPD Study (SmithKline Beecham, SB207499-168, Phase III). Subinvestigator, 2001-2002. A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Ariflo (15 mg bid) in Patients with Chronic Obstructive Pulmonary Disease (COPD).

47. Asthma Study (Genentech, Q2143g, Phase III). Principal Investigator, 2001-2002. A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO)

48. Rhinitis Study (Merck, PAR 246). Principal Investigator, 2001-2002. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (Protocol 246-00)

49. Asthma Study (GlaxoSmithKline, SAS40036). Principal Investigator, 2001-2002. A Multi-center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 16-Week Comparison of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 mcg BID, Fluticasone Propionate DISKUS 100 mcg BID, Salmeterol Xinafoate DISKUS 50mcg BID, or Oral Montelukast 10MG QD

50. Asthma Study (Novartis, CFOR258D2307, Phase III). Principal Investigator. 2002. A randomized, multicenter, placebo-controlled parallel group study of four month's duration per patient to evaluate the safety and efficacy of treatment with 24mcg b.i.d. and 12mcg b.i.d. formoterol, double-blind, and 12mcg b.i.d. formoterol with additional on-demand formoterol doses, open-label, in adolescent and adult patients with persistent stable asthma

PHARMACEUTICAL STUDIES (cont'd)

51. Asthma Study (Astra-Zeneca, SD-039-0726, Phase III). Principal Investigator, 2003-2004.

A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Study of SYMBICORT pMDI Administered Once Daily in Adults and Adolescents with Asthma – STEM

52. Asthma Study (Sepracor, Protocol 051-355, Phase III). Principal Investigator, 2003. A Double-Blind, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study Evaluating the Safety and Efficacy of 90 micrograms Levalbuterol, 180 micrograms Racemic Albuterol and Placebo

53. Asthma Study (Hoffmann-LaRoche, Protocol BA16631, Phase II). Principal Investigator, 2003-2004. Dose-ranging Study of Ro 27-2441 in Patients With Persistent Asthma Not Treated
With Inhaled Corticosteroids

54. Asthma Study (Pharmacia/Pfizer, Protocol PDEAAS 1500-002, Phase III),. Principal Investigator, 2003-2004. A 24 Week, Double-Blind, Randomized, Placebo –Controlled Clinical Trial to
Evaluate the Efficacy and Safety of Oral Roflumilast (250mcg or 500mcg) Daily in Patients with Asthma

55. COPD Study (Pharmacia, Protocol PDEACO-9287-001, Phase III). Principal Investigator, A 24-Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs. Placebo on Pulmonary Function and Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease

56. Asthma Study (Aventis, Protocol XRP1526B-3027, Phase III). Principal Investigator, 2004-2005. A Multi-Center, Multinational, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide HFA-MDI 640 mcg/Day and Beclomethasone HFA-MDI 640 mcg/Day on Lens Opacification in Adult Subjects with Moderate to Severe Persistent Asthma

57. COPD Study (GSK, Protocol SCO40041, Phase III), Principal Investigator, 2004-2007. A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50 mcg BID via DISKUS versus Salmeterol 50 mcg BID via DISKUS on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD).

58. Perennial Allergic Rhinitis Study (Altana, Protocol BY9010/M1-403, Phase III). Principal Investigator, 2005. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Clinical Trial Designed to Assess the Efficacy and Safety of Ciclesonide Applied As a Nasal Spray at Three Dose Levels (200mcg, 100 mcg, or 25 ,mcg once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 6-11 Years of Age

PHARMACEUTICAL STUDIES (cont'd)

59. Sinusitis Study (Bayer, Protocol 100569, Phase IV). Principal Investigator 2004-2005. Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial eradication and key Symptom Relief in the treatment of Acute Bacterial Maxillary Sinusitis with Moxifloxacin 400 mg QD

60. COPD Study (GSK, Protocol SCO40043, Phase 3), Principal Investigator, 2004-2005. A Randomized, Double-Blind, Parallel-Grpi 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS™ Combination Product 250/50mcg BID with Salmeterol DISKUS 50 mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic obstructive Pulmonary Disease (COPD)

61. Chronic Bronchitis Study (Aventis, Protocol HMR 3647A/4020, Phase IV), 2004-2005. An open-label, randomized, multi-center, clinical study to compare the effects of telithromycin, azithromycin and cefuroxime axetil on the penicillin or macrolide resistance of Streptococcus pneumoniac in patients with acute exacerbation of chronic bronchitis

62. Seasonal Allergic Rhinitis Study (Alcon, Protocol C-04-20, Phase 3), Principal Investigator, 2005. Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray in Pediatric Patients

63. Extract Injection Study (Hollister-Stier, HS-JT-OO-OO1A). Principal Investigator, September 2000. Comparison of the J-Tip Needleless Syringe to a Conventional Syringe in the Administration of Allergic Extract

64. Antigen Study (Hollister Stier, HS-AP-OO-OO1A). Principal Investigator, October 2000. "Quantitative Intradermal Procedure to Determine Relative Potency and Compositional Differences Between AP(R) Dog and Regular Process Dog Allergenic Extracts"

65. Antigen Study (Hollister Stier, Protocol HS-AG-OO-OO1R). Principal Investigator November 2000 "Quantitative Procedure to Determine Relative Potency and Compositional Differences Between Diafiltered Short Ragweed Allergenic Extract and Two Commercially Available Short Ragweed Allergenic Extracts"

66. Asthma Study (GlaxoSmithKline, SLGA 5011), (SMART). Principal Investigator, 2000. "Salmeterol Multicenter Asthma Research Trial Study".

67. Asthma Study (Genentech, Protocol Q2196n), (TENOR). Principal Investigator, 2000-2003. An Observational Study of the Epidemiology and Natural History of Asthma: Outcome and Treatment Regimens".

68. Asthma Study (Genentech, Protocol Q2948g), (EXCELS). Principal Investigator, 2004-2009. "An Epidemiological Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma".

PHARMACEUTICAL STUDIES (cont'd)

69. Asthma Study (Novartis, Protocol #CIGE025AUS23, Phase IV), (CLUSTER). Principal Investigator, 2006-2007. "A 26 –Week, Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Multi- Center Study to Evaluate the effect of Xolair on Improving the tolerability of specific Immuno-Therapy in Patients with at least Moderate Persistent Allergic Asthma Inadequately Controlled with Inhaled Corticosteroids."

70. Hereditary Angioedema Study (LEV Pharmaceuticals, LEVP2005-1, Phase III). Principal Investigator, 2006-2007. "C-1 Inhibitor in Hereditary Angioedema Nanofiltration Generation Evaluating Efficacy Trial"

71. Allergy Study (Kendle International, GrassMATAMPL301, Phase III). Principal Investigator, 2007-2007. "Efficacy and Safety/Tolerability of Grass MATA MPL, a Randomized, Placebo-Controlled, Double-Blind Study".

72. Allergic Rhinitis (Sanofi-Aventis, XRG5029C/3503, Phase IIIa). Principal Investigator, 2007-2008. "A Randomized, Multi-center, Double-Blind, Placebo-Controlled, Parallel Group Study of the 12 Month Effect of Treatment with Once Daily Triamcinolone Acetonide (NASACORT AQ Nasal Spray 100ug) on the Growth Velocity of Children 3-9 Years of Age, with Perennial Allergic Rhinitis".

73. Severe Disease to Assess Asthma Control, Allergies, Patient Outcomes and Treatment Study. (CHARIOT). Retrospective Chart Review Study 2007

74. Combivent Study (Boehringer Ingelheim, 1012.56, (Phase 3). Sub Investigator, 2006 – 2008. "A comparison of ipratropium bromide/salbutasmol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12 week, double-blind, safety and efficacy study in adults with chronic obstructive pulmonary disease

75. Crescendo Study (Sanofi Aventis, SR141716, (Phase 3). Sub Investigator 2005 – present. "Randomized, multinational, multi-center, double-blind, placebo-controlled, two-arm parallel group trial of rimonaqabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors."

76. COPD/Inhaled Insulin, (Pfizer, A2171030, phase III). Sub Investigator 2006 – 2007. "Efficacy and Safety of Inhaled Human Insulin (Exubera). Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease. A One-Year Multi center, Randomized Outpatient, Open-Label, Parallel Group Comparative Trial."

77. Asthma/Inhaled Insulin, (Pfizer, A2171028, phase III). Sub Investigator 2006 – 2007. "Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared with Subcutaneous Human Insulin in the Therapy of Adult Subjects with Type 1 or Type 2 Diabetes Mellitus and Chronic Asthma. A One Year Multi-center Randomized, Outpatient, Open-Label, Parallel-Group Comparative Trial."

PHARMACEUTICAL STUDIES (cont'd)

78. Osteoarthritis/Rheumatoid Arthritis, (Pfizer, A3191172, Phase IV) Sub Investigator 2006 – present. "A Randomized, Double-Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease comparing Celecoxib with Naproxen and Ibuprofen."

79. Pneumonia, (Enanta Pharmaceuticals, Inc., EDP420-05-006, phase IIa), Sub Investigator 2005 – 2006 "A Randomized, Double-Blinded, Parallel Group, Multi-Center study of EDP-420 versus Telithromycin for the Treatment of Community Acquired Pneumonia."

80. Diabetes, (Novartis, CLAF237A23119, Phase 3b), Sub Investigator 2006 – present. "A multi-center, randomized, open-label, active controlled, parallel arm study to compare the efficacy of 12 weeks of treatment with Vildagliptin 100 mg, qd to thiazolidinedione (TZD) as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy in a community-based practice setting."

81. Insomnia, (Takeda, 01-05-TL-375-069), Sub Investigator 2007 – present. "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Demonstrate the Subjective Treatment Effects of Ramelteon on Sleep Using a Post Sleep Questionnaire-Interactive Voice Response System (PSQ-IVRS) in an "At Home Setting" in an Adult Population with Chronic Insomnia."

82. Gout, (TAP Pharmaceutical Products, Inc, F-GT06-153, Phase 3), Sub Investigator 2006 – present. "A Randomized, Multi-Center, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects with Gout."

83. COPD (Glasko-Smith-Kline, SCO100250, phase), Sub Investigator, 2007-2008. "A Randomized, Double-Blind, Parallel-Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 250/50 bid with Salmeterol DISKUS 50 mcg bid on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)."

84. Asthma (AstraZeneca, D5896C00025 phase), Sub Investigator, 2006-2008, "A two-week, Randomized, Double-Blind Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Pre-dose Versus Post-dose in Adult Subjects (≥18 years of age) with Mild to Moderate Asthma, Receiving SYMBICORT pMDI 80/4.5 ug x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 ug x 2 Actuations Twice Daily."

85. Asthma (Genentech Q3662g, EXTRA phase), Principal Investigator, 2006-2008, "A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled High-Dose Inhaled Corticosteroids and Long-Acting Beta-Antagonists."

86. Asthma (Schering-Plough, P04828), Principal Investigator, 2007-2008, "A Study of the Therapeutic Equivalency of MF DPI 100 mcg and 200 mcg Inhalers in Corticosteroid-Dependent Subjects with Moderate Asthma."

PHARMACEUTICAL STUDIES (cont'd)

87. Asthma (Boehringer Ingelheim, 1012.56), Sub Investigator, 2006-2008, "A Comparison of Ipratropium Bromide / Salbutamol Delivered by the Respimat Inhaler to Combivent Inhalation Aerosol and Ipratropium Bromide Delivered by the Respimat."

88. Conjunctivitis (Alcon, SMA-07-03, phase IV). After Market Research, 2007. "Pataday Allergic Conjunctivitis Evaluation)PACE) Trial, a Multi-site, Open-Label Study of Patient Perception of the Use of Olapatadine 0.2% with Patients who Previously used Other Ocular Anti-Allergy Medication."

89. COPD (Boehringer Ingelheim, 1205.14, phase) Sub Investigator, 2007-2008. "A Multi-National, Randomized, Double-Blind, Placebo and Activated-Controlled, Parallel Group Efficacy and Safety Comparison over 24 weeks of Three Doses (50 ug, 100 ug, 200 ug) of BEA 2180 to Tiotropium 5 ug and Placebo Delivered by the Respimat Inhaler in Patients with Chronic Obstructive Pulmonary Disease (COPD)."

90. Pneumonia (Boehringer Ingelheim, 1205.14, phase) Sub Investigator, 2007-2008. " A Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 10 days Versus Levofloxacin in the Treatment of Community-Acquired Pneumonia."

91. Asthma (Glasko-Smith-Kline, FFA109684), Principal Investigator. 2008 "A Randomized, Double-Blind, Double Dummy, Placebo controlled, Parallel Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500 mcg Twice Daily Compared with Placebo for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on a Moderate Dose of ICS Therapy."

92. Asthma (Glasko-Smith-Kline, FFA109685), Principal Investigator. 2008 "A Randomized, Double-Blind, Double Dummy, Placebo Controlled, Parallel Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 250 mcg Twice Daily Compared with Placebo for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on a Low Dose of ICS Therapy."

93. Asthma(Glasko-Smith-Kline, FFA109687), Principal Investigator. 2008 "A Randomized, Double-Blind, Double Dummy, Placebo Controlled, Parallel Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 100 mcg Twice Daily Compared with Placebo for 8 weeks in Adolescent and Adult Subjects with Persistent Asthma Symptomatic on Non-Steroidal Asthma therapy."

PHARMACEUTICAL STUDIES (cont'd)

94. Ocular Safety. (Glasko-Smith-Kline, FFR110537), Principal Investigator. 2008. "A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter, Two-year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110 mcg in Adults and Adolescents 12 Years of Age and Older with Perennial Allergic Rhinitis."

95. COPD (Novartis) Sub-investigator. 2008. A 12-week treatment, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructive pulmonary disease.

96. Sublingual Immunotherapy (Schering Plough P05239-children, P05238-adults) Principal Investigator. 2008-2009 "A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Sublingual Immunotherapy with SCH 697243 (*Phleum Pratense*) in Adults and Children with a History of Grass Pollen Induces Rhinoconjunctivitis With or Without Asthma."

97. Pneumonia. (Wyeth 6115A1-3000) Principal Investigator. 2009. "A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 70 Years and Older Who Received 1 Dose of 23-valent Pneumococcal Polysaccharide Vaccine at Least 5 Years Before Study Enrollment."

98. COPD (Forest LAS-MD-36) Investigator. 2009. "Aclidinium Bromide (muscarinic antagonist) Inhaler at two Dosage Levels Administered to Patients with Moderate to Severe COPD."

99. COPD (GSK-HZC102871) Investigator. 2009. "52 week Efficacy and Safety Study to Compare three Dosages of Fluticasone Furoate with a New LABA vs. New LABA Alone on the Annual Rate of Exacerbations in Subjects with COPD."

100. Chronic Idiopathic Urticaria (Health Outcomes Solutions). Investigator. 2008-2009. "A Qualitative Telephone Interview Study in Adult Patients with Chronic Idiopathic Urticaria."

101. Chronic Idiopathic Urticaria (Genentech Q4577g). Principal Investigator. 2009 "A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Xolair (Omalizumab) in Patients with Chronic Idiopathic Urticaria who Remain Symptomatic with Antihistamine (H1)."

102. Asthma (Novartis CIGE025AUS33). Sub-Investigator. 2008-2009. "A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of omalizumab on Markers of Asthma Impairment in Patients with Persistent Allergic Asthma."

PHARMACEUTICAL STUDIES (cont'd)

103. Hereditary Angioedema (ViroPharma 0624-400) Principal Investigator. 2009-2010. "A Phase IV Study to Evaluate the Safety and Effect of Escalating Doses of Cinryze (C1 inhibitor [Human]) as Prophylactic Therapy in Subjects with Inadequately Controlled Hereditary Angioedema Attacks."

104. Asthma (Molly) Phase II trial. Principal Investigator. 2009-2010. "A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult patients With Asthma Who Are Not Taking Inhaled Corticosteroids."

105. Acute H1N1 Tamiflu Phase IV trial. Principal Investigator. 2009-2010. "A Randomized, Multicenter Trial of Oseltamivir Doses of 75 mg for 5 or 10 Days in Influenza Patients with pandemic (H1N1) 2009."

106. COPD Phase III trial. Sub-Investigator. 2009-2010. "A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD)."

107. COPD Phase III trial. Sub-Investigator. 2009-2010. "Phase III, One-Year, randomized, Open-label Safety and Patient Acceptability Study of Combivent Respimat (ipatropium bromide and albuterol sulfate) (20/100 mcg) Inhalation Spray in Comparison to Combivent Inhalation Aerosol (36/206 mcg) and the Free Combination of Atrovent HFA (ipatropium bromide HFA) Inhalation Aerosol (34 mcg) and Albuterol HFA Inhalation Aerosol (180 mcg) in Adults with Chronic Obstructive Pulmonary Disease (COPD)."

108. Perennial Allergic Rhinitis (PAR) Phase III trial. Principal Investigator 2009-2010. "Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 (0.15% solution) and MP03-33 (0.10% solution) in Children Ages ≥6 to <12 with Perennial Allergic Rhinitis."

109. Hereditary Angioedema (ViroPharma 0624-200) Phase II trial. Principal Investigator. 2010-2011. "An open-label, multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze™ in adolescents and adults with hereditary angioedema (Protocol 0624-200)."

110. Pediatric Asthma. (Astra-Zeneca AB D589GC00001) Principal Investigator. 2010. "A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 µg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma."

PHARMACEUTICAL STUDIES (cont'd)

111. Allergic Conjunctivitis (ISTA S00041) Phase II trial. Principal Investigator. 2010. "A randomized, double-masked, placebo-controlled, parallel group confirmatory natural exposure study of the safety and effectiveness of Bepreve (bepotastine besilate ophthalmic solution) 1.5% for the treatment of seasonal allergic conjunctivitis associated with nasal allergy symptoms."

112. COPD. Sub Investigator. 2010. "A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (Advair Diskus) in Comparison to Salmeterol 50 mcg BID (Serevent Diskus) on the Rate of Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Following Hospitalizations."

113. COPD. (Boerhinger Ingelheim) Sub-Investigator. 2010. A COPD study comparing Tiotropium handihaler vs. Tiotropium Respimat.

114. Asthma (Biota) Principal Investigator. 2010. "A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Study of BTA798 in Asthmatic Adults with Symptomatic Human Rhinovirus Infection."

115. CIU (Genentech) Principal Investigator. 2011. "A Phase III, multicenter randomized, double blind, dose ranging placebo controlled study to evaluate the efficacy response duration and safety of Xolair in patients with chronic idiopathic urticaria who remain symptomatic despite antihistamine treatment."

116. Hereditary Angioedema (ViroPharma). Principal Investigator. 2011. "Open label single dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different doses of Cinryze for treatment of acute Angioedema attacks in children less than 12 years of age with hereditary Angioedema.

117. Hereditary Angioedema (CSL Behring) 2011 Principal Investigator. Patient Registry for Berinert®, a C1-Esterase Inhibitor. Multi-center, non-interventional, post marketing patient registry to evaluate the safety of intravenous administration of Berinert in patients requiring treatment with C1-INH in the United States

118. Asthma (Genentech XPORT) 2011 Principal Investigator. A Phase IV, multicenter, randomized, double-blind, placebo-controlled study evaluating the persistency of response with or without Xolair after long-term therapy.

119. Hereditary Angioedema (Shire) Principal Investigator. 2011. A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Hereditary Angioedema.

PHARMACEUTICAL STUDIES (cont'd)

120. Hereditary Angioedema (Pharming) Principal Investigator. 2011. A Phase III randomized, double-blind, placebo-controlled study with an open-label extension evaluating the efficacy, safety and immunogenicity of recombinant human C1 inhibitor for the treatment of acute attacks of angioedema in patients with HAE

121. Asthma (GlaxoSmithKline) Principal Investigator. 2011. SAS115359, a safety and efficacy study of inhaled fluticasone propionate / salmeterol and combination versus inhaled fluticasone propionate in the treatment of adolescent and adult subjects with asthma.

122. Grass Allergy (Merck) Principal Investigator. 2011-2012. A multicenter, double-blind, randomized, placebo-controlled, parallel-group study evaluating the efficacy and safety of grass (Phleum pretense) sublingual tablets (SCH 697243) in subjects between 5 and 65 years of age, with a history of grass pollen-induced rhinoconjunctivitis, with or without asthma.

123. Allergic Conjunctivitis (ISTA) Sponsor/Principal Investigator. 2012. An open label study to evaluate the effectiveness of Bepreve® (bepotastine besilate ophthalmic solution) 1.5% in reducing ocular itching, redness and tearing in subjects with symptomatic seasonal allergic conjunctivitis during grass and / or pine pollen season.

124. Asthma (Cephalon) Principal Investigator. 2011. A 16-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of reslizumab (3.0 mg/kg) treatment in patients with moderate to severe asthma.

125. Asthma (Genentech) Principal Investigator. 2012. Phase IIB Randomized double blind Placebo Controlled study to evaluate the efficacy and safety and dosing regimens of MEMP1972A in Adults with Allergic Asthma who are inadequately controlled on inhaled corticosteroids and a second controller (COSTA).

126. Asthma (Teva) Principal Investigator. 2012. A 12-week dose-ranging study to evaluate the efficacy and safety of Fp Spiromax® (fluticasone propionate inhalation powder) administered twice daily compared with placebo in adolescent and adult subjects with persistent asthma uncontrolled on non-steroidal therapy.

127. Asthma (Dey) Principal Investigator. 2012. A 12-week randomized, multiple-dose, double-blind, placebo-controlled, parallel-group study to evaluate nebulized fluticasone propionate (FP) dose response in adult subjects with partly controlled and uncontrolled asthma.

128. Asthma (Genentech) Principal Investigator. 2012. A phase III randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication.

PHARMACEUTICAL STUDIES (cont'd)

129. Asthma (Teva) Principal Investigator. 2012. A 12-week dose-ranging study to evaluate the efficacy and safety of Fp Spiromax® (fluticasone propionate inhalation powder) administered twice daily compared with placebo in adolescent and adult subjects with severe persistent asthma uncontrolled on high dose inhaled corticosteroid therapy.

130. COPD (GlaxoSmithKline) Sub-Investigator. 2007. A randomized, double-blind, parallel-group clinical trial evaluating the effect of the fluticasone propionate/salmeterol combination product 250/50mcg bid via DISKUS versus Salmeterol 50mcg bid via DISKUS on bone mineral density in subjects with chronic obstructive pulmonary disease (COPD).

131. Primary Immune Deficiency (Kedrion) Principal Investigator. 2013. Multicenter, Open-label, Historically Controlled, Phase III Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Kedrion IVIG 10% in Adult and Pediatric Subjects with Principal Immunodeficiency (PID)

132. Cat Allergy (Circassia). Principal Investigator. 2013. A double Blind Randomised Placebo Controlled Multi center field study to assess the efficacy and safety of Cat PAD Peptide immunotherapy in cat allergic subjects.

133. Dust Mite Allergy (Merck). Principal Investigator. 2013. A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet xxx in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctovitis With or Without Asthma

134. Hereditary Angioedema (ViroPharma) Principal Investigator. 2013. A phase 2, randomized, double-blind, multicenter, dose-ranging, crossover study to evaluate the safety and efficacy of Cinryze® (C1 Esterase Inhibitor [Human]) with recombinant human hyaluronidase (rHUPH20) for the prevention of angioedema attacks in adolescents and adults with hereditary angioedema.

135. Diabetes (Lilly), Principal Investigator, 2013. A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: **A**ssessment of **W**eekly **A**dminist**R**ation of **LY2189265** in **D**iabetes - 8).

136. Asthma (Dey), Principal Investigator, 2013. A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects with Partly Controlled and Uncontrolled Asthma

PHARMACEUTICAL STUDIES (cont'd)

137. COPD (Pearl), Principal Investigator, 2013. A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva Handihaler (Tiotropium Bromide 18 ug, Open-Label) as an Active Control.

138. Asthma (Genentech), Principal Investigator, 2013. A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma who are on Inhaled Corticosteroids and a second Controller Medication.

139. Sinusitis (Optinose), Principal Investigator, 2014. A 12-Month Open Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400ug of Fluticasone Propionate Twice a Day BID Using a Novel Bi-Directional Device in Subjects with Chronic Sinusitis with or without polyps.

140. Sinusitis (Optinose), Principal Investigator, 2014. A 3 Month Opel Label Multicenter Study Evaluating the Safety and Intranasal Administration of 400ug of Fluticasone Propionate Twice a Day BID Using a Novel Bi-Directional Device in Subjects with Chronic Sinusitis with or without nasal polyps.

141. Pruritis (TigerCat), Principal Investigator, 2014. A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritus.

142. Grass Allergy (Circassia), Principal Investigator, 2014. An observational multicentre field study to assess symptom scores and allergy medication usage in subjects with a history of grass induced rhinoconjunctivitis.

143. Pediatric Asthma (TEVA), Principal Investigator, 2014. A three week multicenter randomized double blind placebo controlled chronic dose safety and efficacy and study of albuterol multi dose drug powder inhaler (MDPI) relative to placebo in pediatric asthmatics.

144. Asthma (AstraZeneca), Principal Investigator, 2014. A multicenter randomized double blind parallel group placebo controlled phase 3 efficacy and safety study of Benralizumab (MEDI 563) added to medium dose inhaled corticosteroid plus long acting β agonist in patients with uncontrolled asthma (PAMPERO).

145. Asthma (Mylan), Principal Investigator, 2014. A randomized double blind double dummy parallel group study to determine the local equivalence of multiple doses of MGR001 to
Advair Diskus administered via oral inhalation in adult asthma patients.

PHARMACEUTICAL STUDIES (cont'd)

146. Asthma (Novartis), Principal Investigator, 2014. A long term natural history of patients with severe or difficult to treat asthma from the TENOR observational study.

147. Hereditary Angioedema (CSL Behring), Principal Investigator, 2014. A double blind randomized placebo controlled cross over study to evaluate the clinical efficacy and safety of subcutaneous administration of human plasma derived C1 esterase inhibitor in the prophylactic treatment of hereditary angioedema.

148. Asthma (Teva), Principal Investigator, 2014. A 12-week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of XXX Multidose Dry Powdered Inhaler and XXX Multidose Dry Powdered Inhaler in Adolescents and Adult Patients with Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy

149. COPD (Mylan), Principal Investigator, 2014. A Randomized, Double-Blind, Parallel Group, 24 Week Placebo-Controlled, Efficacy and Safety Study with a 28 Week Long-Term Extension of Nebulized XXX/XXX Combination Compared with FP and FF Monotherapy in Patients with COPD

150. Asthma (Teva), Principal Investigator,2014. A 26-Week Open-Label Study to Assess the Long-Term Safety of XXX Multidose Dry Powder Inhaler and XXX/XXX Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma

151. Atopic Dermatitis (Regeneron), Principal Investigator, 2014-15. A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate to Severe Atopic Dermatitis.

152. Hereditary Angioedema (Dyax), Principal Investigator, 2014-15. Measuring Contact Pathway Biomarkers in Subjects Diagnosed with Hereditary Angioedema (HAE).

153. Hereditary Angioedema (BioCryst), Principal Investigator, 2014-15. OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema (HAE).

154. Atopic Dermatitis (Anacor), Principal Investigator, 2014-15. A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis